This was the second of a two part investigation looking at concerns about a pivotal trial for the anti-clotting drug, rivaroxaban. In this investigation, Deborah found that companies were aware of concerns about a faulty device in a regulatory trial
One of the world’s largest hip replacement firms, DePuy, has admitted “an error in the measuring techniques” when making controversial metal-on-metal implants. Read more: https://www.telegraph.co.uk/news/investigations/patients-given-hip-implants-made-the-wrong-size/
This award winning investigation investigated why doctors in England’s NHS have been left seemingly unable to prescribe a cheap, safe, and effective drug despite its flourishing use elsewhere. It unearthed conflicts of interest in the NHS and medical charities; a lack of transparency by regulations; and a distortion of European law.
In the first of a two part investigation, Deborah used internal documents and US and EU regulatory documents obtained under freedom of information to find out what was known about the use of this oral anticoagulant. She found that the company had conducted analyses about how to make its use safer – but hadn’t shared these with global drug regulators. The story got international media coverage and led to regulatory action.
Sports drinks are increasingly regarded as an essential adjunct for anyone doing exercise, but the evidence for this view is lacking.In a joint investigation, Deborah combined data with investigative journalism to explore the claims made by companies and the impact on hydration guidelines. Do people need to drink ahead of their thirst? And do sports drinks hydrate faster than water?
With concern over metal on metal hip implants mounting, Deborah examined the evidence of risk from metal-on-metal hip implants finding longstanding concerns over their use. Deborah used a combination of the US regulator’s devices database, internal documents and a review of the scientific literature in her approach. The story received international media coverage and led to changes in clinical guidance.
Studies to test the safety and efficacy of drugs and medical devices are too often never made public, putting lives at risk. When she was Investigation Editor at The BMJ, Deborah explored these complex issues for Index on Censorship